Zai Lab Shares Surge Over 7% Intraday as Zoci Plus Atezolizumab First-Line ES-SCLC Data Debuts at ESMO

Deep News10-26

Zai Lab Ltd (SEHK: 09688) shares climbed more than 7% intraday, and as of press time the stock was up 5.91% at HK$18.83, with turnover of HK$32.42179 million.

On October 23, Zai Lab Ltd (SEHK: 09688) announced the first data from a global Phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with atezolizumab (with or without carboplatin) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the 2026 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.

Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab Ltd (SEHK: 09688), said: "Despite continued advances in treatment, extensive-stage small cell lung cancer remains a highly devastating disease, with many patients experiencing disease progression approximately five months after starting standard first-line therapy. The confirmed high response rate, encouraging durability, and well-tolerated safety profile we observed with this chemotherapy-free regimen are particularly notable. We believe that zoci, with both efficacy and safety, has the potential to become the preferred ADC backbone for small cell lung cancer, including in combination with immunotherapy."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106000455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-26 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106000455","market":"other","top_or_hot":-1,"title":"Zai Lab Shares Surge Over 7% Intraday as Zoci Plus Atezolizumab First-Line ES-SCLC Data Debuts at ESMO","media":"Deep News","content":"<p>Zai Lab Ltd (SEHK: 09688) shares climbed more than 7% intraday, and as of press time the stock was up 5.91% at HK$18.83, with turnover of HK$32.42179 million.<br><br>On October 23, Zai Lab Ltd (SEHK: 09688) announced the first data from a global Phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with atezolizumab (with or without carboplatin) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the 2026 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.<br><br>Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab Ltd (SEHK: 09688), said: \"Despite continued advances in treatment, extensive-stage small cell lung cancer remains a highly devastating disease, with many patients experiencing disease progression approximately five months after starting standard first-line therapy. The confirmed high response rate, encouraging durability, and well-tolerated safety profile we observed with this chemotherapy-free regimen are particularly notable. We believe that zoci, with both efficacy and safety, has the potential to become the preferred ADC backbone for small cell lung cancer, including in combination with immunotherapy.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Shares Surge Over 7% Intraday as Zoci Plus Atezolizumab First-Line ES-SCLC Data Debuts at ESMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Shares Surge Over 7% Intraday as Zoci Plus Atezolizumab First-Line ES-SCLC Data Debuts at ESMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-10-26 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab Ltd (SEHK: 09688) shares climbed more than 7% intraday, and as of press time the stock was up 5.91% at HK$18.83, with turnover of HK$32.42179 million.<br><br>On October 23, Zai Lab Ltd (SEHK: 09688) announced the first data from a global Phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with atezolizumab (with or without carboplatin) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the 2026 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.<br><br>Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab Ltd (SEHK: 09688), said: \"Despite continued advances in treatment, extensive-stage small cell lung cancer remains a highly devastating disease, with many patients experiencing disease progression approximately five months after starting standard first-line therapy. The confirmed high response rate, encouraging durability, and well-tolerated safety profile we observed with this chemotherapy-free regimen are particularly notable. We believe that zoci, with both efficacy and safety, has the potential to become the preferred ADC backbone for small cell lung cancer, including in combination with immunotherapy.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1106000455","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106000455","pubTimestamp":1792979433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Zai Lab Ltd (SEHK: 09688) shares climbed more than 7% intraday, and as of press time the stock was up 5.91% at HK$18.83, with turnover of HK$32.42179 million.On October 23, Zai Lab Ltd (SEHK: 09688)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK1574":"生物医药B类股","ZLAB":"再鼎医药","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4531":"中概回港概念","BK4588":"碎股","BK4526":"热门中概股","BK1588":"回港中概股","09688":"再鼎医药","BK1161":"生物科技","BK4548":"巴美列捷福持仓"},"translate_title":"Zoci Plus Atezolizumab 一线 ES-SCLC 数据在 ESMO 首次亮相，再鼎医药股价盘中飙升超过 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1,"09688":1},"content_text":"Zai Lab Ltd (SEHK: 09688) shares climbed more than 7% intraday, and as of press time the stock was up 5.91% at HK$18.83, with turnover of HK$32.42179 million.On October 23, Zai Lab Ltd (SEHK: 09688) announced the first data from a global Phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with atezolizumab (with or without carboplatin) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the 2026 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab Ltd (SEHK: 09688), said: \"Despite continued advances in treatment, extensive-stage small cell lung cancer remains a highly devastating disease, with many patients experiencing disease progression approximately five months after starting standard first-line therapy. The confirmed high response rate, encouraging durability, and well-tolerated safety profile we observed with this chemotherapy-free regimen are particularly notable. We believe that zoci, with both efficacy and safety, has the potential to become the preferred ADC backbone for small cell lung cancer, including in combination with immunotherapy.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106000455","isCrawlerRequest":true}